Related Experiment Videos
An ARE-selective DNA minor groove binder from a combinatorial approach
F Hamy1, G Albrecht, A Flörsheimer
1Department of Oncology, Novartis Pharma Research, Basel, CH-4002, Switzerland. francois.hamy@pharma.novartis.com
Biochemical and Biophysical Research Communications
|February 7, 2001
Summary
Researchers identified CGL-6382, a novel molecule that selectively binds to androgen receptor elements (AREs). This discovery highlights a new method for finding sequence-specific DNA-binding ligands.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Biochemistry
Background:
- Developing sequence-specific DNA-binding ligands is crucial for molecular biology and drug discovery.
- Identifying ligands that target specific DNA sequences like androgen receptor elements (AREs) presents a significant challenge.
Purpose of the Study:
- To screen a synthetic combinatorial library for inhibitors of DNase I cleavage at ARE sequences.
- To identify and characterize novel ARE-selective DNA-binding ligands using DNase I footprinting.
Main Methods:
- A synthetic combinatorial library of 10,000 peptide ligands was generated using ten amino acid building blocks.
- DNase I footprinting assays were employed to screen the library and identify DNA-binding molecules.
- Sublibrary synthesis and deconvolution were used to isolate and optimize lead compounds.
Main Results:
- The compound CGL-6382 was identified as an ARE-selective minor groove binder.
- CGL-6382 recognizes a specific 5'-GC(A/T)(A/T) motif within ARE sequences.
- The ligand features a N-terminal nicotinic acid motif, N-methylimidazole, N-methylpyrrole units, and a C-terminal argininamide.
Conclusions:
- The DNase I footprinting methodology is effective for identifying sequence-specific DNA recognition ligands from complex mixtures.
- CGL-6382 represents a promising ARE-selective ligand with potential applications in molecular biology and therapeutics.
- This study validates a powerful approach for discovering novel DNA-interacting small molecules.